ReviewDiscover oncology2026
Dietary polyphenols and hepatocellular carcinoma: protective mechanisms, challenges, and future directions.
Review in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide, with pathogenesis driven by metabolic reprogramming, oxidative stress, chronic inflammation, and dysregulation of multiple signaling pathways. Dietary polyphenols-a structurally diverse group of phytochemicals abundant in fruits, vegetables, tea, and medicinal plants-have emerged as promising chemopreventive and therapeutic agents due to their pleiotropic bioactivities. This comprehensive review systematically searched PubMed/MEDLINE, Web of Science, Scopus, and Google Scholar for relevant literature published from 2014 to 2025. It outlines the molecular mechanisms through which dietary polyphenols (including phenolic acids, flavonoids, lignans, stilbenes, and others) suppress HCC development by modulating lipid metabolism, glucose homeostasis, mitochondrial function, oxidative stress, inflammatory responses, and detoxification pathways. Special emphasis is placed on their ability to reshape the tumor microenvironment (TME) and their synergistic potential when combined with conventional treatments. Nevertheless, the clinical translation of polyphenols is hampered by limitations such as poor bioavailability, chemical instability, and insufficient clinical validation. Future efforts should prioritize the development of advanced delivery systems (e.g., nanoformulations), investigation of polyphenol-drug synergies, and validation through rigorously designed clinical trials. This review underscores the promise of dietary polyphenols as complementary agents for HCC prevention and treatment, while highlighting the imperative for further mechanistic and translational research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.